Shares in Allergy Therapeutics (LON:AGY) are currently trading close to a 52 week high, with the share price up by around 7.25% - to 35.5p - over the past week. On a one-month basis, the Allergy Therapeutics share price has risen by 20...
AGY — Allergy Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall CapFalling Star
- £125.58m
- £94.12m
- £84.33m
- 59
- 31
- 22
- 27
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.28 | ||
| Price to Tang. Book | 2.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.59 | ||
| EV to EBITDA | 560.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.75% | ||
| Return on Equity | -9.47% | ||
| Operating Margin | -5.48% | ||
Financial Summary
| Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 64.14 | 68.35 | 73.72 | 78.2 | 84.33 | 77.59 | 81.82 | 11.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +102.32 | -59.26 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for AGY
With shares in Allergy Therapeutics (LON:AGY) currently trading close to a 52 week high, a question many on the sidelines probably have is: "was I too late to buy them"? The share price is up by around 2.48% over the past week. On a on...
Contrarian value investors are always on the look-out for shares that the market has overlooked. In times of economic uncertainty - when stock prices become erratic - good quality stocks can become cheaper. The question is whether LON:...
Research shows that quality and value are two powerful drivers of stock market profits. After the economic turmoil and market volatility we've seen over the past year, it's possible that these two factors could have an influence on the...
Research shows that quality and value are two powerful drivers of stock market profits. After the economic turmoil and market volatility we've seen over the past year, it's possible that these two factors could have an influence on the...
Profile Summary
Allergy Therapeutics plc is a United Kingdom-based commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. It sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
Directors
- Peter Jensen NEC
- Manuel Llobet CEO
- Nicolas Wykeman CFO
- Sara Goldsbrough SEC
- Scott Leinenweber NED (49)
- Cheryl Macdiarmid NED (53)
- Babatunde Otulana NID
- Mary Tavener NID (60)
- Last Annual
- June 30th, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- June 1st, 2004
- Public Since
- October 11th, 2004
- No. of Employees
- 601
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 643,998,996
- Address
- Dominion Way, WORTHING, BN14 8SA
- Web
- http://www.allergytherapeutics.com/
- Phone
- +44 1903844700
- Auditors
- BDO LLP
Latest News for AGY
Upcoming Events for AGY
Similar to AGY
4Basebio
London Stock Exchange
4d Pharma
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
What is the Allergy Therapeutics share price?
As of Today at 07:00 UTC, shares in Allergy Therapeutics are trading at 19.50p. This share price information is delayed by 15 minutes.
How has the Allergy Therapeutics share price performed this year?
Shares in Allergy Therapeutics last closed at 19.50p and the price had moved by -22% over the past 365 days. In terms of relative price strength the Allergy Therapeutics share price has underperformed the FTSE All Share Index by -19.52% over the past year.
What are the analyst and broker recommendations for Allergy Therapeutics?
The overall consensus recommendation for Allergy Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Allergy Therapeutics dividend yield?
Allergy Therapeutics does not currently pay a dividend.
Does Allergy Therapeutics pay a dividend?
Allergy Therapeutics does not currently pay a dividend.
When does Allergy Therapeutics next pay dividends?
Allergy Therapeutics does not currently pay a dividend.
How do I buy Allergy Therapeutics shares?
To buy shares in Allergy Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Allergy Therapeutics?
As of the previous close price of 19.50p, shares in Allergy Therapeutics had a market capitalisation of £125.58m.
Where are Allergy Therapeutics shares listed?
Here are the trading details for Allergy Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AGY
What kind of share is Allergy Therapeutics?
Based on an overall assessment of its quality, value and momentum Allergy Therapeutics is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Allergy Therapeutics share price forecast for 2022?
The analyst consensus target price for shares in Allergy Therapeutics is 59.00p. That is 202.56% above the last closing price of 19.50p.
Analysts covering Allergy Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -£0.02 for the next financial year.
What is the trend in the Allergy Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allergy Therapeutics. Over the past six months, its share price has underperformed the FTSE All Share Index by -32.3%.
As of the last closing price of 19.50p, shares in Allergy Therapeutics were trading -30.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Allergy Therapeutics PE Ratio?
The Allergy Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 19.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Allergy Therapeutics?
Allergy Therapeutics' management team is headed by:
- Peter Jensen - NEC
- Manuel Llobet - CEO
- Nicolas Wykeman - CFO
- Sara Goldsbrough - SEC
- Scott Leinenweber - NED
- Cheryl Macdiarmid - NED
- Babatunde Otulana - NID
- Mary Tavener - NID